Kimryn Rathmell, Chief Executive Officer of Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, shared a post on LinkedIn:
“I’d like to give a shoutout to our team from The James at ASH25 sharing our world-class hematology oncology science. We’re showing up in a big way, with 100+ presentations that exemplify how we’re redefining what is possible along the spectrum of Blood Cancers.
If you’ll be there, please find our experts and strike up a conversation. Our booth is # 181 and our presentation schedule is in the link.
To give you an appetizer, it’s a chance to hear how James scientists are:
• Engineering the future: Reaching new frontiers of CAR T-cell therapy and A.I. to transform how we understand and treat blood cancers
• Targeting resistance: Leading clinical trials for novel inhibitors – such as next-generation BTK inhibitors – aimed at overcoming the most challenging cases of treatment resistance
• Pioneering precision: Learning how to better evaluate cancer risk and optimizing therapies to treat aggressive leukemias in vulnerable adults.”
Read More Updates from ASH25 on OncoDaily.